The European Medicines Agency (EMA) seeks to streamline and clarify the operational framework for combination products within the in vitro diagnostics (IVD) sector, aiming to balance regulatory oversight and industry innovation. This update triggers attention among diagnostic manufacturers, regulatory authorities, healthcare providers, and patient groups, all stakeholders impacted by changes in coordination and compliance procedures.
This report was published on January 7, 2026, by the EMA’s internal Combination Products Operational Group (COMBO), specifically the In Vitro Diagnostics stream. The document provides a detailed highlight report—a status update rather than a legislative proposal.
This highlight report outlines current operational status, evaluates existing coordination mechanisms between regulatory bodies, and suggests improvements. It does not present new legislation nor binding mandates but includes recommendations to enhance efficiency and clarity in the classification and oversight of combination products involving IVDs. No specific numerical targets, budget allocations, or institutional restructuring are contained within this document; it functions primarily as an evaluative and orientative report.
The EMA’s policy orientation seems to prioritize refining the regulatory environment through better integration of operational groups to enhance the predictability of authorization procedures and reduce complexities in IVD combination product assessments. This indicates a move toward increased institutional coordination at the EU level, potentially raising the regulatory scrutiny for IVD-related products to ensure consistent application of rules, possibly at the expense of added administrative steps for industry players.
For industry stakeholders—IVD manufacturers and developers—this report may signal a tightening of operational oversight, which could increase compliance demands and development timelines, posing moderate challenges. Regulatory authorities might benefit from improved clarity and streamlined protocols, enhancing their supervisory capabilities. Healthcare providers and patients stand to gain from potentially higher safety and efficacy standards through strengthened coordination, although changes might initially slow product availability.
This document represents a continuing process of operational refinement within the EMA’s regulatory structure. We can anticipate follow-up actions by EMA committees and possibly reactions or adaptations by national competent authorities. The report lays groundwork potentially influencing future formal policy proposals or updates in EU medical device regulations related to combination products.